ARS Pharmaceuticals (NASDAQ: SPRY) net income
ARS Pharmaceuticals reported a net loss of $171.3m for fiscal 2025; in fiscal 2024 it reported a net profit of $8.0m. Earnings per share were −$1.74.
ARS Pharmaceuticals's best year of the last 6 was fiscal 2024. It reported a loss in 5 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$171.3m | −2,241.8% | −203.3% | −$1.74 |
| 2024 | $8.0m | — | 9.0% | $0.08 |
| 2023 | −$54.4m | — | −181,216.7% | −$0.57 |
| 2022 | −$34.7m | — | −2,635.4% | −$0.87 |
| 2021 | −$20.2m | — | −367.7% | −$0.70 |
| 2020 | −$32.9m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ARS Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, ARS Pharmaceuticals ranks 397th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of ARS Pharmaceuticals, −203.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 395th | Edgewise Therapeutics | −$167.8m | — |
| 396th | Cabaletta Bio | −$167.9m | — |
| 397th | ARS Pharmaceuticals | −$171.3m | −203.3% |
| 398th | Armata Pharmaceuticals | −$173.8m | — |
| 399th | Solid Biosciences | −$174.3m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of ARS Pharmaceuticals
- How much did ARS Pharmaceuticals earn in fiscal 2025?
- ARS Pharmaceuticals reported a net loss of $171.3m for fiscal 2025. In fiscal 2024 it reported a net profit of $8.0m.
- What are the earnings per share of ARS Pharmaceuticals?
- They were −$1.74 in fiscal 2025, compared with $0.08 in fiscal 2024.
- What was the most profitable year for ARS Pharmaceuticals?
- Of its last 6 fiscal years, fiscal 2024, with $8.0m.
- Where does ARS Pharmaceuticals rank in its sector by net income?
- It ranks 397th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for ARS Pharmaceuticals come from?
- From the annual report (Form 10-K) that ARS Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ARS Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on ARS Pharmaceuticals: the ARS Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.